Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Open accessAbstract
After the first attachment of virus to the cell surface through a primary receptor, efficient entry of virus requires the presence of a coreceptor. For adeno-associated virus type 2 (AAV2) infection, heparan sulfate proteoglycan is supposed as the primary receptor, and αvβ5 integrin and FGFR1 are reported to act as coreceptors. In this study, we were able to demonstrate that hepatocyte growth factor receptor, c-Met, is also a coreceptor for AAV2 infection. AAV2-mediated transgene analyses revealed that c-Met expression significantly up-regulated transgene expression without increasing AAV2 cell binding. Moreover, a viral overlay assay elucidated the physical interaction between AAV2 and the β subunit of c-Met. These data suggest that c-Met plays the role of coreceptor for AAV2 infection by facilitating AAV2 internalization into the cytoplasm.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The early steps of AAV infection involve attachment to a variety of cell surface receptors such as HSPG, FGFR, αvβ5 integrin, and hepatocyte growth factor receptor (c-Met), followed by clathrin-dependent endocytosis.
“The early steps of AAV infection involve attachment to a variety of cell surface receptors such as HSPG, FGFR, αvβ5 integrin, and hepatocyte growth factor receptor (c-Met) (Fig. 8I) (9, 25, 31, 39, 40), followed by clathrin-dependent endocytosis (Fig.8II).”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [25]
The opening summary identifies HSPG as the primary attachment receptor and FGFR1, αvβ5 integrin, and c-Met as AAV2 coreceptors. The Discussion also reports AAV2 internalization from clathrin-coated pits. However, the Results say c-Met did not increase AAV2 cell attachment, so describing c-Met as an attachment receptor is not supported. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102 · see citing works
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Woude, G. F. V., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,226 · see citing works
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199 · see citing works
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,409 · see citing works
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Woude, G. F. V. (1984) · Nature · doi:10.1038/311029a0 · Cited by 991 · see citing works
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749 · see citing works
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711 · see citing works
Emerging Multipotent Aspects of Hepatocyte Growth Factor
Matsumoto, K., & Nakamura, T. (1996) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021283 · Cited by 666 · see citing works
Self-citationPurification and subunit structure of hepatocyte growth factor from rat platelets
Nakamura, T., Nawa, K., Ichihara, A., Kaise, N., & Nishino, T. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80475-1 · Cited by 548 · see citing works
Self-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1× · see citing works
“by on January 25, 2010 jvi.asm.org Downloaded from ( 2 ).”
BackgroundExpression of the Met/HGF receptor in normal and neoplastic human tissues.
Renzo, M. F. D., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Médico, E., Gaglia, P., Zara, P., & Comoglio, P. M. (1991) · PubMed · Cited by 474 · see citing works
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443 · see citing works
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339 · see citing works
Adeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lü, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J. C., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · see citing works
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Rong, S., Bodescot, M., Blair, D. G., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A. M.-L., Aaronson, S. A., & Woude, G. F. V. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5152 · Cited by 312 · see citing works
Self-citationPrat, M., Narsimhan, R. P., Crepaldi, T., Nicotra, M., Natali, P. G., & Comoglio, P. M. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490302 · Cited by 287 · see citing works
Grimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195 · see citing works
Linear DNAs Concatemerize in Vivo and Result in Sustained Transgene Expression in Mouse Liver
Chen, Z.-Y., Yant, S. R., He, C.-Y., Meuse, L. A., Shen, S., & Kay, M. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0278 · Cited by 186 · see citing works
Goldman, M., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.10.5951-5958.1995 · Cited by 186 · see citing works
Mochizuki, H., Hayakawa, H., Migita, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo-Nakanishi, Y., Urabe, T., YAMADA, M., Tamayose, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191107398 · Cited by 164 · see citing works
Self-citationRecombinant AAV serotype 1 transduction efficiency and tropism in the murine brain
Wang, C., Wang, C.-M., Clark, K. R., & Sferra, T. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302011 · Cited by 139 · see citing works
Expression of the C– Met Protooncogene in Human Hepatocellular Carcinoma
Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., et al. (1994) · Hepatology · doi:10.1002/hep.1840200520 · Cited by 125 · see citing works
Guo, C., Li, Y., Tian, S., Wang, X., Douglas, S. D., & Ho, W. (2002) · Journal of Investigative Medicine · doi:10.1136/jim-50-06-03 · Cited by 119 · see citing works
Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein
Mizukami, H., Young, N. S., & Brown, K. E. (1996) · Virology · doi:10.1006/viro.1996.0099 · Cited by 106 · see citing works
Expression of β1, β3, β4, and β5 Integrins by Human Lung Carcinoma Cells of Different Histotypes
Falcioni, R., Cimino, L., Gentileschi, M. P., D’Agnano, I., Zupi, G., Kennel, S. J., & Sacchi, A. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1017 · Cited by 84 · see citing works
Tumorigenicity of the met Proto-Oncogene and the Gene for Hepatocyte Growth Factor
Rong, S., Bodescot, M., Blair, D. G., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A. M.-L., Aaronson, S. A., & Woude, G. F. V. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5152-5158.1992 · Cited by 83 · see citing works
Self-citationWendtner, C., Kofler, D. M., Theiss, H. D., Kurzeder, C., Buhmann, R., Schweighofer, C. D., Perabò, L., Danhauser-riedl, S., Baumert, J. J., Hiddemann, W., et al. (2002) · Blood · doi:10.1182/blood.v100.5.1655.h81702001655_1655_1661 · Cited by 77 · see citing works
Lyon, M., Deakin, J. A., & Gallagher, J. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107506200 · Cited by 76 · see citing works
Axon-Schwann cell interactions regulate the expression of c-jun in Schwann cells
Shy, M. E., Shi, Y., Wrabetz, L. G., Kamholz, J. A., & Scherer, S. S. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960301)43:5 · Cited by 74 · see citing works
Self-citationBiochemical study of KB-cell receptor for adenovirus
Hennache, B., & Boulanger, P. A. (1977) · Biochemical Journal · doi:10.1042/bj1660237 · Cited by 65 · see citing works
Protein Kinase C Controls Microtubule-based Traffic but Not Proteasomal Degradation of c-Met
Kermorgant, S., Zicha, D., & Parker, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302116200 · Cited by 63 · see citing works
Mitchell, M., Jerebtsova, M., Ml, B., Newman, K. D., & Ye, X. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301332 · Cited by 62 · see citing works
Cooper, C. S., Tempest, P. R., Beckman, M., Heldin, C., & Brookes, P. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04543.x · Cited by 62 · see citing works
Lock, L. S., Frigault, M. M., Saucier, C., & Park, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302675200 · Cited by 51 · see citing works
Barani, A. E., Sabido, O., & Freyssenet, D. G. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00030-7 · Cited by 20 · see citing works
Guo, C., Li, Y., Tian, S., Wang, X., Douglas, S. D., & Ho, W. (2002) · Journal of Investigative Medicine · doi:10.1097/00042871-200211010-00027 · Cited by 16 · see citing works
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · see citing works
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · see citing works
“Internalization is enhanced by interactions with one or more of at least six known coreceptors including V5 integrins (63), fibroblast growth factor receptor 1 (53), hepatocyte growth factor receptor ( 35 ), v1 integrin (7), and laminin receptor (3).”
BackgroundAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 921 · see citing works
“Subsequent interactions with human fibroblast growth factor receptor 1 (FGFR1) [73], hepatocyte growth factor receptor [74], and integrins aVh5/a5h1 ([75], A.”
BackgroundZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · see citing works
An essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532 · see citing works
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Samulski, R. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 463 · see citing works
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430 · see citing works
“However, we hypothesize that since AAV2 uses at least four other receptors (16, 22, 28, 29), blocking one (LamR) might have only marginal effects on AAV2 binding.”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419 · see citing works
“8I) (9, 25, 31, 39, 40), followed by clathrin-dependent endocytosis (Fig.”
In vivo tissue-tropism of adeno-associated viral vectors
Srivastava, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.003 · Cited by 346 · see citing works
Wu, Z., Miller, E. B., Agbandje‐McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 327 · see citing works
“AAV2, which has been demonstrated to use integrin V 5, basic fibroblast growth factor receptor, or hepatocyte growth factor receptor as its coreceptor for cell entry (20, 30, 41), was much less sensitive to proteinase K treatment for transduction (Fig.”
BackgroundVarious AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 319 · see citing works
“The developed strategies suggested different approaches, mainly, capsid modification of AAV3 vectors [76,80,81] and modification of hHGFR expression levels, along with the tyrosine kinase activity associated with it [78].”
BackgroundInfluentialSonntag, F., Bleker, S., Leuchs, B., Fischer, R., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.01056-06 · Cited by 277 · see citing works
“Infection of cultured cells by adeno-associated virus type 2 (AAV2) is initiated by binding to heparan sulfate proteoglycan as an attachment receptor followed by interaction with either human fibroblast growth factor receptor 1, integrin V 5, or hepatocyte growth factor receptor (35, 50, 62, 63).”
BackgroundNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267 · see citing works
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. F. V. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 266 · see citing works
“AAV2 virions utilize as primary attachment receptor heparan sulphate proteoglycans [20] while internalisation is aided by the co-receptors αvβ5 integrin heterodimers [21], fibroblast growth factor receptor type 1 [22] and the hepatocyte growth factor receptor, c-Met [23].”
BackgroundEllis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252 · see citing works
“In some cases our results did not match perfectly with previous results [23] (for example AAV1, AAV2, AAV5 on C2C12 cells; AAV1, AAV2, AAV5 on CHOK1 cells).”
BackgroundInfluentialIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258 · see citing works
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242 · see citing works
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · see citing works
“Several fundamental steps in the life cycle of AAV2 vectors, such as viral binding and entry (Kashiwakura et al., 2005; Qing et al., 1999; Summerford et al., 1999; Summerford and Samulski, 1998), intracellular trafficking (Douar et al., 2001; Hansen et al., 2000, 2001; Sanlioglu et al., 2000; Zhao…”
BackgroundAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215 · see citing works
Lochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · see citing works
“Besides heparan sulfate (48), the v 5 integrin receptor (47), the fibroblast growth factor receptor FGFR1 (37), and the hepatocyte growth factor receptor (24) have also been proposed to be receptors required for AAV-2 transduction.”
BackgroundTwenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197 · see citing works
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191 · see citing works
Pillay, S., Zou, W., Cheng, F., Puschnik, A. S., Meyer, N., Ganaie, S. S., Deng, X., Wosen, J. E., Davulcu, O., Yan, Z., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00391-17 · Cited by 190 · see citing works
“Following this work, several proteinaceous coreceptors, such as fibroblast growth factor receptor 1 (FGFR-1) (18), integrin V 5 (19), and the hepatocyte growth factor receptor (c-Met) (20), were implicated in AAV2 entry.”
BackgroundRecent developments in adeno‐associated virus vector technology
Büning, H., Perabò, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. J. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 189 · see citing works
“AAV-1 Not described Not described AAV-2 Heparan sulphate proteoglycan (HSPG) [30] FGFR-1 [170] HGFR, c-met [171] Laminin receptor [172] αvβ5 [173] α5β1 [31] AAV-3 Heparan sulphate proteoglycan (HSPG) [69,174,175] FGFR-1 [174] Laminin receptor [172] AAV-4 O-linked sialic acid [176] AAV-5 N-linked sialic acid [176] Plat…”
BackgroundAsokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183 · see citing works
“In addition, AAV also appears to utilize several coreceptors, such as fibroblast growth receptor 1 and hepatocyte growth receptor by AAV2 (21, 31) and platelet-derived growth receptor by AAV5 (5), for successful cellular entry.”
BackgroundGrieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · see citing works
“7, step 1) (6, 26, 43, 52, 53) followed by clathrin-mediated”
Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics
Rayaprolu, V., Kruse, S., Kant, R., Venkatakrishnan, B., Movahed, N., Brooke, D. J., Lins, B., Bennett, A. D., Potter, T., McKENNA, R. V., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01415-13 · Cited by 161 · see citing works
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155 · see citing works
“…(HSPG) is the primary receptor for AAV2, which can utilize aVb5 integrin, fibroblast growth factor receptor-1, or hepatocyte growth factor receptor as co-receptors for internalization after binding to the cell surface (Kashiwakura et al. 2005; Qing et al. 1999; Summerford and Samulski 1998).”
BackgroundHoward, D. B., Powers, K., Wang, Y., & Harvey, B. K. (2008) · Virology · doi:10.1016/j.virol.2007.10.007 · Cited by 149 · see citing works
“, 1999), hepatocyte growth factor receptor (Kashiwakura et al., 2005) and laminin receptor (Akache et al.”
BackgroundLi, Z., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Lakshmanan Govindasamy, A., Agbandje‐McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 146 · see citing works
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. J., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 140 · see citing works
“AAV2 6-O- and N-sulfated heparin Fibroblast [108]/hepatocyte [109] growth factor receptor; laminin receptor [110]; integrin αVβ5 [111] and α5β1 [112]”
BackgroundTargeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145 · see citing works
“Co-receptors such as the integrins Itgav and Itgb5 [66,67], hepatocyte growth factor receptor (c-MET) [68], and fibroblast growth factor receptor 1 (FGFR1) [69,70] have been implicated in AAV attachment and internalization, from which the integrins are expressed in microglia.”
Adeno-associated virus (AAV) cell entry: structural insights
Meyer, N., & Chapman, M. S. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.005 · Cited by 139 · see citing works
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 134 · see citing works
GPR108 Is a Highly Conserved AAV Entry Factor
Dudek, A. M., Zabaleta, N., Zinn, E. M., Pillay, S., Zengel, J. R., Porter, C. L., Franceschini, J. S., Estelien, R., Carette, J. E., Zhou, G. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.005 · Cited by 128 · see citing works
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122 · see citing works
Adeno-associated virus-2 and its primary cellular receptor—Cryo-EM structure of a heparin complex
O’Donnell, J., Taylor, K. A., & Chapman, M. S. (2009) · Virology · doi:10.1016/j.virol.2008.11.037 · Cited by 126 · see citing works
“…and integrins αVβ1 and αVβ5, though the latter has been questioned (Akache et al., 2006; Asokan et al., 2006; Blackburn, Steadman, and Johnson, 2005; Kashiwakura et al., 2005; Qing et al., 1999; Qiu and Brown, 1999; Smith, Collaco, and Trempe, 2004; Summerford, Bartlett, and Samulski, 1999).”
BackgroundClinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 122 · see citing works
“…binding of AAV serotype 2 (AAV2) is heparan sulphate (Summerford and Samulski, 1998), with avb5 integrin (Summerford et al., 1999), fibroblast growth factor-1 (Qing et al., 1999), hepatocyte growth factor (Kashiwakura et al., 2005) and laminin all implicated as coreceptors (Akache et al., 2006).”
BackgroundAn Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor
Dudek, A. M., Pillay, S., Puschnik, A. S., Nagamine, C. M., Cheng, F., Qiu, J., Carette, J. E., & Vandenberghe, L. H. (2018) · Journal of Virology · doi:10.1128/jvi.02213-17 · Cited by 116 · see citing works
Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 116 · see citing works
The Role of the Adeno-Associated Virus Capsid in Gene Transfer
Vliet, K. V., Blouin, V., Brument, N., Agbandje‐McKenna, M., & Snyder, R. O. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_2 · Cited by 113 · see citing works
“After binding the cell surface, AAV2 can utilize secondary receptors, such as αVβ5 integrin, human fibroblast growth factor receptor-1 (FGFR-1), or hepatocyte growth factor (c-met), which mediate entry [44] [45] [46] [47] .”
BackgroundAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114 · see citing works
Vulchanova, L., Schuster, D. J., Belur, L. R., Riedl, M. S., Podetz-Pedersen, K. M., Kitto, K. F., Wilcox, G. L., McIvor, R. S., & Fairbanks, C. A. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-31 · Cited by 114 · see citing works
“For example, AAV2 utilizes heparan sulfate proteoglycans as receptors and a number of other cell-surface molecules, such as fibroblast growth factor receptor 1 and hepatocyte growth factor receptor, as co-receptors [22-26].”
BackgroundHeparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110 · see citing works
“Efficient AAV2 infection also requires a co-receptor, such as human fibroblast growth factor receptor 1 (FGFR1), integrins avb5 and a5b1, or hepatocyte growth factor receptor (Asokan et al., 2006; Kashiwakura et al., 2005; Summerford et al., 1999; Qing et al., 1999).”
BackgroundPopa-Wagner, R., Porwal, M., Kann, M., Reuss, M., Weimer, M., Florin, L., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00282-12 · Cited by 109 · see citing works
“The infection cycle of AAV2 is initiated by binding to cellular receptors, including heparan sulfate proteoglycan, v 5 integrin, 5 1 integrin, fibroblast growth factor receptor 1, hepatocyte growth factor receptor 1, and 36/67-kDa laminin receptor (1, 4, 31, 46, 53, 54) and subsequent endocytosis into the cell.”
BackgroundAdeno-associated virus 2 bound to its cellular receptor AAVR
Zhang, R., Cao, L., Cui, M., Sun, Z., Hu, M., Zhang, R., Stuart, W. S., Zhao, X., Yang, Z., Li, X., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0356-7 · Cited by 106 · see citing works
Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features
Mietzsch, M., Jose, A., Chipman, P. R., Bhattacharya, N., Daneshparvar, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Viruses · doi:10.3390/v13010101 · Cited by 103 · see citing works
“Among the cellular receptors are sialic acids [22–24], heparan sulfate proteoglycans (HSPG) [25–29], terminal galactose [30,31], sulfated N-acetyl-lactosamine [32], AAVR [33], laminin [34], αvβ1 integrin [35], αvβ5 integrin [36], the hepatocyte growth factor receptor [37], the fibroblast growth factor receptor [38], a…”
BackgroundLing, C., Lu, Y., Kalsi, J. K., Jayandharan, G. R., Li, B., Ma, W., Cheng, B., Gee, S. W. Y., McGoogan, K. E., Lakshmanan Govindasamy, A., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.075 · Cited by 100 · see citing works
“We next wished to examine whether AAV3 uses murine HGFR as a coreceptor in an animal model in vivo , especially because HGFR has been shown to be a coreceptor for AAV2 (Kashiwakura et al ., 2005), and because transduction by both”
InfluentialHost determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 94 · see citing works
RNA interference approaches for treatment of HIV-1 infection
Bobbin, M. L., Burnett, J., & Rossi, J. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0174-y · Cited by 93 · see citing works
“For example, AAV2 targets heparan sulfate proteoglycan, αVβ5 integrin and fibroblast growth receptor 1, which is found on hepatocytes, skeletal muscle cells, smooth muscle cells, and neurons [146].”
BackgroundPipe, S. W., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.015 · Cited by 92 · see citing works
Gabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90 · see citing works
“…kinase to the tyrosines on the AAV2 capsid, the surface exposure of which may be determined in part by specific receptor and coreceptor binding as well as by the varied endosomal processing in these tissues (Qing et al., 1999; Kaludov et al., 2001; Kashiwakura et al., 2005; Seiler et al., 2006).”
BackgroundStructure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5 Å Resolution
Lerch, T. F., O’Donnell, J., Meyer, N., Xie, Q., Taylor, K. A., Stagg, S. M., & Chapman, M. S. (2012) · Structure · doi:10.1016/j.str.2012.05.004 · Cited by 89 · see citing works
“(Recent studies suggest that AAV serotypes, all of which vary structurally at VR-I, use several serotype-specific co-receptors for cell entry (Akache et al., 2006; Di Pasquale and Chiorini, 2003; Kashiwakura et al., 2005; Ling et al., 2010; Qing et al., 1999).)”
Stieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Meur, G. L., Weber, M., Deschamps, J.-Y., Lorenz, B., Moullier, P., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.283 · Cited by 88 · see citing works
A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery
Yu, C.-Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., & Xiao, X. (2009) · Gene Therapy · doi:10.1038/gt.2009.59 · Cited by 88 · see citing works
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 88 · see citing works
Akache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 85 · see citing works
“[8] [9] [10] [11] In contrast, AAV5 preferentially attaches to cells by binding to sialic acid and the platelet-derived growth factor receptor, 12, 13 explaining the distinct tissue tropisms displayed by this serotype.”
BackgroundGrieger, J. C., Johnson, J. S., Gurda-Whitaker, B., Agbandje-McKenna, M., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00580-07 · Cited by 83 · see citing works
“The early steps of AAV2 infection begin with attachment to heparan sulfate proteoglycan and to a variety of cell surface receptors, such as FGFR, V 5 integrin, 5 1 integrin, and hepatocyte growth factor receptor (c-Met) (4, 14, 22, 32, 38, 39), followed by clathrin dependent endocytosis.”
BackgroundRoyo, N. C., Vandenberghe, L. H., Ma, J.-Y., Hauspurg, A. K., Yu, L., Maronski, M., Johnston, J., Dichter, M. A., Wilson, J. M., & Watson, D. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.11.015 · Cited by 82 · see citing works
Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier
Albright, B. H., Storey, C. M., Murlidharan, G., Castellanos Rivera, R. M., Berry, G. E., Madigan, V. J., & Asokan, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.017 · Cited by 82 · see citing works
Custom Adeno-Associated Virus Capsids: The Next Generation of Recombinant Vectors with Novel Tropism
Muzyczka, N., & Warrington, K. H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.408 · Cited by 80 · see citing works
Altering AAV tropism with mosaic viral capsids
Gigout, L. I., Rebollo, P., Clement, N., Warrington, K. H., Muzyczka, N., Linden, R. M., & Weber, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.005 · Cited by 79 · see citing works
López-Bueno, A., Rubio, M., Bryant, N. D., McKENNA, R. V., Agbandje‐McKenna, M., & Almendral, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1563-1573.2006 · Cited by 79 · see citing works
“Molecules with specific binding properties or functional activity as parvovirus receptors have been identified for some members of the family, such as the ABP protein for the Aleutian disease virus (28); some globosides and the 5 1 integrin for the human parvovirus B19 (12, 40, 88); transferrin receptors for canine (C…”
BackgroundInfluentialChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 78 · see citing works
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 77 · see citing works
“Comparison of five promoters for transgene expression AAV2 cell entry is primarily achieved by binding heparin sulfate proteoglycans [77–81] and interacting with co-receptors on the cell surface such as the adeno-associated virus receptor [82, 83], the 37/67-kilodalton laminin receptor [84], αVβ5 integrin [85], hepato…”
BackgroundTumor vascular targeting therapy with viral vectors
Liu, Y., & Deisseroth, A. (2005) · Blood · doi:10.1182/blood-2005-10-4114 · Cited by 74 · see citing works
The parvovirus capsid odyssey: from the cell surface to the nucleus
Harbison, C. E., Chiorini, J. A., & Parrish, C. R. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.01.012 · Cited by 73 · see citing works
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 69 · see citing works
“More recently, Kashiwakura described AAV2 using hepatocyte growth factor as a co-receptor, Asokan showed integrin α5β1 binds AAV2 and that binding increases the efficiency of transduction, andAkache demonstrated that AAV2, 3, 8 and9 bind the 37/67 laminin receptor [29–31].”
BackgroundRetinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 68 · see citing works
“AAV2 is the best characterized serotype and therefore several binding partners on the cell surface were identified including heparan sulfate proteoglycan [53] and different possible co-receptors such as the fibroblast growth factor receptor 1 [54], aVb5 integrin [55], hepatocyte growth factor receptor [56] and laminin…”
BackgroundManini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 66 · see citing works
Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8
Mietzsch, M., Barnes, C., Hull, J. A., Chipman, P. R., Xie, J., Bhattacharya, N., Sousa, D. R., McKENNA, R. V., Gao, G., & Agbandje‐McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01769-19 · Cited by 66 · see citing works
“, AAVR (38), laminin (39), v 1 integrin (40), v 5 integrin (41), the hepatocyte growth factor receptor (42), the fibroblast growth factor receptor (43), and platelet-derived growth factor receptor (44).”
BackgroundLee, S. H., Tang, Y.-Q., Rathakrishnan, A., Wang, S. M., Ong, K. C., Manikam, R., Payne, B. J., Jaganath, I. B., & Sekaran, S. D. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-192 · Cited by 66 · see citing works
“The HGF receptor (HGFR) has been implied as a co-receptor for adeno-associated virus type 2 infections [43], and although this has not been shown for dengue virus entry, the HGF per se has been found to be increased in the serum of dengue infected patients [44].”
Michelfelder, S., Lee, M., deLima-Hahn, E., Wilmes, T., Kaul, F., Müller, O. J., Kleinschmidt, J. A., & Trepel, M. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.07.018 · Cited by 63 · see citing works
Adeno-Associated Virus 2 at 2.8 ang
Lou, Z. Y., & Zhang, R. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6ih9/pdb · Cited by 66 · see citing works
AAVR: A Multi-Serotype Receptor for AAV
Summerford, C., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.49 · Cited by 61 · see citing works
Hondermarck, H., Bartlett, N. W., & Nurcombe, V. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00015 · Cited by 61 · see citing works
“44 Pharmacological inhibition of the NGF receptor TrkA has been shown to suppress influenza virus replication.”
BackgroundJin, X., Liu, L., Nass, S., O’Riordan, C. R., Pastor, E., & Zhang, X. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.178 · Cited by 62 · see citing works
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61 · see citing works
“In the current paradigm, AAV2 transduction is initiated by capsid binding to HSPG as a primary receptor, followed by interaction with coreceptors (19–24).”
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 61 · see citing works
“…have roles in AAV2 binding and transduction (e.g., fi broblast growth factor receptor 1 (FGFR1) [91], α V β 5 and α 5 β 1 integrin [92–94], hepatocyte growth factor receptor (HGFR) [95], and laminin receptor (LR) [96]) but, later, could not be validated as essential factors in transduction [97–99].”
BackgroundCheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G., Park, M., Stacpoole, P. W., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 58 · see citing works
Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 54 · see citing works
“For example, the hepatocyte growth factor receptor (c-MET) and human fibroblast growth factor receptor-1 (FGFR1) were identified as possible protein co-receptors for AAV2 [175,176].”
BackgroundParvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje‐McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 53 · see citing works
Watanabe, M., Nasu, Y., Kashiwakura, Y., Kusumi, N., Tamayose, K., Nagai, A., Sasano, T., Shimada, T., Daida, H., & Kumon, H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.699 · Cited by 53 · see citing works
Self-citationControlled release strategies for rAAV-mediated gene delivery
Rey‐Rico, A., & Cucchiarini, M. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.015 · Cited by 52 · see citing works
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 48 · see citing works
Cryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 47 · see citing works
Attachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1
Blackburn, S. D., Steadman, R., & Johnson, F. B. (2005) · Archives of Virology · doi:10.1007/s00705-005-0650-6 · Cited by 47 · see citing works
“cell entry receptors or coreceptors for AAV-2 include human FGFR-1 [9], αVβ5 integrin [12], and hepatocyte growth factor receptor (c-Met) [ 6 ].”
BackgroundStructural and cellular biology of adeno-associated virus attachment and entry
Zengel, J. R., & Carette, J. E. (2020) · Advances in virus research · doi:10.1016/bs.aivir.2020.01.002 · Cited by 44 · see citing works
AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
Denard, J., Rouillon, J., Léger, T., Garcia, C., Lambert, M. P., Griffith, G., Jenny, C., Camadro, J., Garcı́a, L., & Svinartchouk, F. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.001 · Cited by 44 · see citing works
Targeted Gene Therapy for the Treatment of Heart Failure
Rapti, K., Chaanine, A. H., & Hajjar, R. J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.02.005 · Cited by 42 · see citing works
Characterization of Interactions between Heparin/Glycosaminoglycan and Adeno-Associated Virus
Zhang, F., Aguilera, J. J., Beaudet, J. M., Xie, Q., Lerch, T. F., Davulcu, O., Colón, W., Chapman, M. S., & Linhardt, R. J. (2013) · Biochemistry · doi:10.1021/bi4008676 · Cited by 41 · see citing works
Kurzeder, C., Koppold, B., Sauer, G., Pabst, S., Kreienberg, R., & Deißler, H. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.2.325 · Cited by 41 · see citing works
Sipo, I., Fechner, H., Pinkert, S., Suckau, L., Wang, X., Weger, S., & Poller, W. C. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302987 · Cited by 40 · see citing works
Enhanced transduction of mouse salivary glands with AAV5-based vectors
Katano, H., Kok, M. R., Cotrim, A. P., Yamano, S., Schmidt, M., Afione, S. A., Baum, B. J., & Chiorini, J. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302691 · Cited by 39 · see citing works
Engineering AAV receptor footprints for gene therapy
Madigan, V. J., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.05.001 · Cited by 37 · see citing works
Jayandharan, G. R., Li, Z., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 37 · see citing works
“…(Akache et al. , 2006) as opposed to the AAV2 sero-type, for which apart from the primary receptor, heparan sulfate proteoglycan (Summerford and Samulski, 1998), at least six different cellular coreceptors are known to exist (Qing et al. , 1999; Summerford et al. , 1999; Kashiwakura et al. , 2005).”
Viral mechanisms for docking and delivering at nuclear pore complexes
Flatt, J. W., & Greber, U. F. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.05.008 · Cited by 36 · see citing works
Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 36 · see citing works
High-Throughput Dissection of AAV–Host Interactions: The Fast and the Curious
Herrmann, A.-K., & Grimm, D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.022 · Cited by 33 · see citing works
Emmanuel, S. N., Mietzsch, M., Tseng, Y.-S., Smith, J. K., & Agbandje‐McKenna, M. (2020) · Viral Immunology · doi:10.1089/vim.2020.0022 · Cited by 33 · see citing works
“The AAVs utilize various glycan and protein receptors (5,32,56,65,82, 96,100,121,128,132) for cell attachment and entry, and thus differ in tissue tropism (42,102,119).”
Background
- Authors
- Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H.
- Affiliations
- Juntendo University (JP)
- Nippon Medical School (JP)
- The University of Osaka (JP)
- Okayama University (JP)
- Departments of Cardiology
- Corresponding author
- Tamayose, Kenji
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2005-01
- Volume
- 79
- Issue
- 1
- Pages
- 609-614
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC538679
- OpenAlex
- W2120683337
- Cited by
- 246
- References
- 37
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 16 · 2020: 10 · 2019: 12 · 2018: 8 · 2017: 13 · 2016: 9 · 2015: 15 · 2014: 8 · 2013: 13 · 2012: 12
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus type 2, c-Met, co-receptors, viral entry, heparan sulfate proteoglycans, integrin αvβ5, FGFR1, transgene expression, viral internalization, receptor interaction
- MeSH terms
- Dependovirus, Animals, Cricetinae, HeLa Cells, Humans, Receptors, Virus, Transduction, Genetic, CHO Cells, 3T3 Cells, Hepatocyte Growth Factor, Proto-Oncogene Proteins c-met, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
